8-Jun-2026
4DMT to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 27-May 8:00 AM ET)
4DMT Announces New Employment Inducement Grants
Globe Newswire (Fri, 15-May 4:05 PM ET)
Globe Newswire (Thu, 7-May 4:05 PM ET)
Globe Newswire (Wed, 18-Mar 4:05 PM ET)
4DMT to Participate in Upcoming Investor Meetings
Globe Newswire (Mon, 16-Mar 8:00 AM ET)
FDMT Secures $100 Million in Fresh Funding: New Offering Expands Clinical Ambitions
Market Chameleon (Thu, 6-Nov 3:05 AM ET)
Market Chameleon (Fri, 31-Oct 3:07 AM ET)
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
4D Molecular Therapeutics trades on the NASDAQ stock market under the symbol FDMT.
As of June 8, 2026, FDMT stock price was flat at $8.64 with 557,851 million shares trading.
FDMT has a beta of 0.54, meaning it tends to be less sensitive to market movements. FDMT has a correlation of 0.01 to the broad based SPY ETF.
FDMT has a market cap of $451.65 million. This is considered a Small Cap stock.
Last quarter 4D Molecular Therapeutics reported $3 million in Revenue and -$1.01 earnings per share. This beat revenue expectation by $223,000 and missed earnings estimates by -$.02.
In the last 3 years, FDMT traded as high as $36.25 and as low as $2.24.
The top ETF exchange traded funds that FDMT belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWN.
FDMT has outperformed the market in the last year with a price return of +98.6% while the SPY ETF gained +24.6%. However, in the short term, FDMT had mixed performance relative to the market. It has underperformed in the last 3 months, returning +1.9% vs +10.2% return in SPY. But in the last 2 weeks, FDMT shares have fared better than the market returning +0.5% compared to SPY -0.9%.
FDMT support price is $8.16 and resistance is $9.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FDMT shares will trade within this expected range on the day.
